Torsade de pointes after administration of droperidol for nausea and vomiting

Prehospital Emergency Care

Volumn 13, Issue 2, 2009, Pages 261-265

  Choo, Esther K ^a   Weber, Frank S ^b   Schmidt, Terri A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b American Medical Response Inc   (United States)

Author keywords

Droperidol; Emergency medical services; QT interval; Torsade de pointes

Indexed keywords

CIMETIDINE; DROPERIDOL; FLUOXETINE; MAGNESIUM; MORPHINE SULFATE; NORTRIPTYLINE; ONDANSETRON; POTASSIUM; SODIUM CHLORIDE; TROPONIN; ANTIEMETIC AGENT;

ABDOMINAL PAIN; ADULT; AMBULANCE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CASE REPORT; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; EPIGASTRIC PAIN; FEMALE; HEADACHE; HEART CATHETERIZATION; HEART VENTRICLE EXTRASYSTOLE; HORMONE SUBSTITUTION; HUMAN; HYPOKINESIA; HYPOTENSION; LENGTH OF STAY; NAUSEA AND VOMITING; PARAMEDICAL PERSONNEL; PATIENT MONITORING; PATIENT TRANSPORT; POLYMORPHIC VENTRICULAR TACHYCARDIA; POTASSIUM BLOOD LEVEL; QT INTERVAL; QT PROLONGATION; RISK FACTOR; SINUS RHYTHM; SINUS TACHYCARDIA; ST SEGMENT DEPRESSION; T WAVE; T WAVE INVERSION; TAKOTSUBO CARDIOMYOPATHY; TORSADE DES POINTES; VITAL SIGN; VOMITING; CHEMICALLY INDUCED; MIDDLE AGED; NAUSEA;

ANTIEMETICS; DROPERIDOL; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; TORSADES DE POINTES; VOMITING;

EID: 70350635628     PISSN: 10903127     EISSN: 15450066     Source Type: Journal    
DOI: 10.1080/10903120802706096     Document Type: Article

References (30)

1. MedWatch 2001 Safety Information Summaries: Inapsine (droperidol) [cited February 1, 2008]. Available at: http://www. fda.gov/medwatch/safety/2001/ safety01.htm#inapsi. Accessed July 1, 2008.
2. Martel M, Miner J, Fringer, R, et al. Discontinuation of droperidol for the control of acutely agitated out-of-hospital patients. Prehosp Emerg Care. 2005;9:44-48
3. Jacoby JL, Fulton J, Cesta M, Heller M. After the black box warning: Dramatic changes in ED use of droperidol.AmJ EmergMed. 2005;23:196.
4. McEvoy GK. Anxiolytics, sedatives, and hypnotics. In: AHFS Drug Information. Bethesda, MD: American Society of Health- System Pharmacists, 2007.
5. Chase P, Biros M. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med. 2002;9:1402-1410
6. Rosen CL, Ratliff AF, Wolfe RE, Branney SW, Roe EJ, Pons PT. The efficacy of intravenous droperidol in the prehospital setting. J Emerg Med. 1997;15:13-17
7. Hick J, Mahoney B, Lappe M. Prehospital sedation with intramuscular droperidol: A one-year pilot. Prehosp Emerg Care. 2001;5:391-394
8. Habib A, Gan T. The use of droperidol before and after the Food and Drug Administration black box warning: A survey of the members of the Society of Ambulatory Anesthesia. J Clin Anesth. 2008;20(1):35-39
9. Apfel CC, Korttila K, Abdalla M, et al. IMPACT Investigators. A factorial trial of six interventions for prevention of postoperative nausea and vomiting. N Engl J Med 2004;350:2441-2451
10. Henzi I, Sonderegger J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anesth. 2000;47:537-551
11. Gan TJ, Meyer TA, Apfel CC, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2007;105:1615-1628
12. Weichenthal L, Soliz T. The incidence and treatment of prehospital motion sickness. Prehosp Emerg Care. 2003;7:474-476
13. Roden D. Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350:1013-1022
14. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med. 2002;112(1):58-66.
15. Al-Khatib SM, LaPointe NMA, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289:2120-2127
16. Resnick M, Burton BT. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychopharmacol. 1984;45(7):298-299
17. Sharma ND, Rosman HS, Padhi D, Tisdale JE. Torsade de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998;81:238-244
18. Warden C, Moreno R, Daya M. Prospective evaluation of ondansetron for undifferentiated nausea and vomiting in the prehospital setting. Prehosp Emerg Care. 2008;12:87-91.
19. Horowitz B, Bizovi K, Moreno R. Droperidol-behind the black box warning. Acad Emerg Med. 2002;9:615-618
20. Kao LW, Kirk MA, Evers SJ, Rosenfeld S. Droperidol, QT prolongation, and sudden death: What is the evidence? Ann Emerg Med. 2003;41:546-558
21. Habib A, Gan T. Food and Drug Administration black box warning on the perioperative use of droperidol: A review of the cases. Anesth Analg. 2003;96:1377-1379
22. Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology. 2007;107:531-536
23. Lischke V, Behne M, Doelken P, Scheldt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg. 1994;79:983-986
24. White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose droperidol on the QT interval during and after general anesthesia: A placebo-controlled study. Anesthesiology. 2005;102:1101-1105
25. Curry S, DeVane C, Wolfe M. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol. 1985;29:429-433
26. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial.AmJ Geriatr Psychiatry. 1997;5:97-106. (Pubitemid 27157393)
27. Chan MT, Choi KC, Gin T, et al. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg. 2006;103:1155-1162
28. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102:1094-1100
29. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270: 2590-2597
30. FDA approves first generic ondansetron injection. US Food and Drug Administration. Available at: Www.fda.gov/bbs/topics/ news/2006/new01513.html. Accessed January 22, 2009.